- Report
- August 2025
- 194 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- August 2025
- 184 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Clinical Trials
- April 2025
- 280 Pages
Global
From €2646EUR$3,000USD£2,290GBP
- Report
- June 2025
- 150 Pages
Global
From €2380EUR$2,699USD£2,061GBP
- Report
- April 2025
- 137 Pages
Asia Pacific
From €3043EUR$3,450USD£2,634GBP
- Report
- April 2025
- 136 Pages
Africa, Middle East
From €3043EUR$3,450USD£2,634GBP
- Report
- May 2024
- 132 Pages
Global
From €5732EUR$6,499USD£4,962GBP
- Report
- May 2024
- 131 Pages
Global
From €5732EUR$6,499USD£4,962GBP
- Report
- April 2023
- 180 Pages
Global
From €2866EUR$3,250USD£2,481GBP
- Report
- October 2023
- 145 Pages
Global
From €2778EUR$3,150USD£2,405GBP
- Report
- May 2024
- 132 Pages
Global
From €5732EUR$6,499USD£4,962GBP
- Report
- August 2024
- 80 Pages
Japan
From €3087EUR$3,500USD£2,672GBP
- Report
- February 2024
- 360 Pages
Global
From €7011EUR$7,950USD£6,070GBP
- Report
- July 2024
- 150 Pages
Global
From €3925EUR$4,450USD£3,397GBP
- Report
- December 2023
- 140 Pages
Global
From €3140EUR$3,560USD£2,718GBP
€3925EUR$4,450USD£3,397GBP
- Report
- November 2020
- 199 Pages
Global
€3969EUR$4,500USD£3,436GBP
- Report
- September 2025
- 50 Pages
Global
From €2337EUR$2,650USD£2,023GBP

Bimatoprost is a medication used to treat glaucoma and other optical disorders. It is a prostaglandin analog, meaning it works by increasing the outflow of fluid from the eye, reducing intraocular pressure. Bimatoprost is available as a topical ophthalmic solution, and is the only prostaglandin analog approved for the treatment of glaucoma and ocular hypertension. It is also used to treat hypotrichosis, a condition characterized by inadequate or thinning eyelashes.
Bimatoprost is a widely used medication in the optical disorders drugs market. It is the most commonly prescribed prostaglandin analog for glaucoma and ocular hypertension, and is also used off-label for other conditions. Bimatoprost is generally well-tolerated, with few side effects.
Some companies in the Bimatoprost market include Allergan, Sun Pharmaceuticals, and Pfizer. Show Less Read more